title: Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.
abstract: BACKGROUND
  Restenosis remains the major limitation of coronary catheter-based intervention. In small vessels, the amount of neointimal tissue is disproportionately greater than the vessel caliber, resulting in higher restenosis rates. In the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, approximately 40% of the vessels were small (<2.5 mm). The present study evaluates the relationship between angiographic outcome and vessel diameter for sirolimus-eluting stents.
  
  
  RESULTS
  Patients were randomized to receive either an 18-mm bare metal Bx VELOCITY (BS group, n=118), or a sirolimus-eluting Bx VELOCITY stent (SES group, n=120). Subgroups were stratified into tertiles according to their reference diameter (RD; stratum I, RD <2.36 mm; stratum II, RD 2.36 mm to 2.84 mm; stratum III, RD >2.84 mm). At 6-month follow-up, the restenosis rate in the SES group was 0% in all strata (versus 35%, 26%, and 20%, respectively, in the BS group). In-stent late loss was 0.01+/-0.25 versus 0.80+/-0.43 mm in stratum I, 0.01+/-0.38 versus 0.88+/-0.57 mm in stratum II, and -0.06+/-0.35 versus 0.74+/-0.57 mm in stratum III (SES versus BS). In SES, the minimal lumen diameter (MLD) remained unchanged (Delta -0.72 to 0.72 mm) in 97% of the lesions and increased (=late gain, DeltaMLD <-0.72 mm) in 3% of the lesions. Multivariate predictors for late loss were treatment allocation (P<0.001) and postprocedural MLD (P= 0.008).
  
  
  CONCLUSIONS
  Sirolimus-eluting stents prevent neointimal proliferation and late lumen loss irrespective of the vessel diameter. The classic inverse relationship between vessel diameter and restenosis rate was seen in the bare stent group but not in the sirolimus-eluting stent group.
authors.affiliation: Thoraxcenter, Rotterdam, The Netherlands.
authors.forename: E
authors.initials: E
authors.lastname: Regar
authors.forename: P W
authors.initials: PW
authors.lastname: Serruys
authors.forename: C
authors.initials: C
authors.lastname: Bode
authors.forename: C
authors.initials: C
authors.lastname: Holubarsch
authors.forename: J L
authors.initials: JL
authors.lastname: Guermonprez
authors.forename: W
authors.initials: W
authors.lastname: Wijns
authors.forename: A
authors.initials: A
authors.lastname: Bartorelli
authors.forename: C
authors.initials: C
authors.lastname: Constantini
authors.forename: M
authors.initials: M
authors.lastname: Degertekin
authors.forename: K
authors.initials: K
authors.lastname: Tanabe
authors.forename: C
authors.initials: C
authors.lastname: Disco
authors.forename: E
authors.initials: E
authors.lastname: Wuelfert
authors.forename: M C
authors.initials: MC
authors.lastname: Morice
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D003331:Coronary Vessels / Q000473:pathology; D004311:Double-Blind Method; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D015607:Stents
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus